Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Radiopharmaceutical Advancements in Anesthesia and Orthopedic Oncology: A Paradigm Shift in Cancer Biotherapy and Targeted Therapy.","authors":"Shu Su, Wanpeng Zheng, Mingbin Huang","doi":"10.1089/cbr.2025.0063","DOIUrl":"https://doi.org/10.1089/cbr.2025.0063","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Integrating radiopharmaceuticals in anesthesia and orthopedic oncology has revolutionized cancer biotherapy and targeted therapy. This multidisciplinary approach leverages molecular imaging, radioisotopes, and precision medicine to enhance perioperative pain management and improve therapeutic efficacy. <b><i>Methods:</i></b> Radiopharmaceutical-based anesthetic techniques (R-ATs) have emerged to facilitate intraoperative monitoring and postsurgical pain control, ensuring better patient outcomes in orthopedic oncology procedures. This article explores combining radiopharmaceuticals with orthopedic cancer management, emphasizing novel theranostic agents, α- and β-emitting radionuclides, in treating metastatic bone disease. Innovations in peptide receptor radionuclide therapy (PRRT) and radiolabeled bisphosphonates have provided a significant leap forward in mitigating skeletal-related events and improving survival rates. <b><i>Results:</i></b> This article discusses radiopharmaceutical-guided anesthesia's role in enhancing intraoperative imaging precision and personalizing analgesic regimens for patients with cancer undergoing orthopedic interventions. The article aligns with recent developments in molecular medicine by addressing the translational impact of radiopharmaceuticals on cancer treatment paradigms. In targeted therapy, R-AT attained an effectiveness of up to 96.25%, while PRRT reached 97.45%. <b><i>Conclusions:</i></b> It highlights integrating artificial intelligence and molecular imaging in real-time surgical decision-making, redefining personalized oncology care. The synergistic use of radiopharmaceuticals in anesthesia and orthopedic oncology holds immense promise in precision-driven therapeutic strategies for cancer biotherapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>MYDGF</i> Regulates Apoptotic Signaling to Mitigate Renal Ischemia-Reperfusion Injury and Enhance Chemotherapy Sensitivity.","authors":"Yan Xu, Jinlong Dai, Biao Huang, Guoyuan Lu","doi":"10.1089/cbr.2025.0077","DOIUrl":"https://doi.org/10.1089/cbr.2025.0077","url":null,"abstract":"<p><p><b><i>Background:</i></b> Chemotherapy sensitivity in renal carcinoma may be influenced by renal ischemia-reperfusion injury (RIRI). This study elucidates the underlying mechanism by investigating the regulatory role of <i>MYDGF</i>. <b><i>Methods:</i></b> The public dataset was downloaded, and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were used to analyze functional and pathway enrichment of genes in the most significant modules. MitoTracker Green and MitoSOX were used to assess mitochondrial activity and superoxide production in oxygen-glucose deprivation/reoxygenation (OGD/R)-treated renal proximal tubular epithelial cells (RPTECs), with or without <i>MYDGF</i> treatment. Reactive oxygen species production and apoptosis were further analyzed through flow cytometry. A mouse model of RIRI was established and treated with <i>MYDGF</i>, followed by kidney evaluation after 24 h. Histological damage was assessed using hematoxylin-eosin and Masson staining in both RIRI mice and IR-induced patients with AKI. Immunohistochemistry and quantitative real-time polymerase chain reaction were performed to evaluate <i>MYDGF</i>, BCL2, and BAX expression levels in renal tissues. <b><i>Results:</i></b> A total of 557 differentially expressed genes were identified. GO and KEGG analyses revealed significant enrichment in oxidative phosphorylation and apoptosis pathways, both of which are relevant to chemosensitivity. <i>MYDGF</i> treatment significantly inhibited apoptosis, enhanced mitochondrial function, and reduced superoxide production in OGD/R-treated RPTECs. <i>In vivo</i>, <i>MYDGF</i> reduced tubular apoptosis and protected against kidney injury, as shown by TUNEL and Masson staining. Notably, <i>MYDGF</i> increased BCL2 and decreased BAX expression both <i>in vitro</i> and <i>in vivo</i>, suggesting an antiapoptotic shift. These changes may contribute not only to protection from RIRI but also to increased susceptibility of damaged renal cells to chemotherapy-induced apoptosis by maintaining mitochondrial integrity. <b><i>Conclusions:</i></b> Regulation of apoptotic signaling by <i>MYDGF</i> attenuates ischemia-reperfusion injury and improves chemotherapy outcomes in advanced renal carcinoma.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Danggui Buxue Decoction Combined with Borneol Improves Cyclophosphamide-Induced Myelosuppression by Inhibiting CDK2.","authors":"Kui Li, Ruoxia Wu, Ting Zhou, Jiaqing Xiong","doi":"10.1089/cbr.2024.0207","DOIUrl":"https://doi.org/10.1089/cbr.2024.0207","url":null,"abstract":"<p><p><b><i>Objective:</i></b> The purpose of this study is to explore the effective components and molecular targets of Danggui Buxue decoction (DBD) combined with borneol (DBD&Bor) in alleviating myelosuppression. <b><i>Methods:</i></b> A network pharmacology strategy was used to identify the active components and key targets of DBD&Bor in the context of myelosuppression. <i>In vivo</i>, the effects of the DBD&Bor and its effective components on cyclophosphamide (CTX)-induced myelosuppression in rats were evaluated through immunohematological analysis, histopathological analysis, and organ index analysis. <i>In vitro</i>, the impact of the effective components of DBD&Bor on CTX-stimulated apoptosis and cell cycle of K562 cells was analyzed using flow cytometry. Finally, the recovery experiment was used to verify further the relationship between the effective ingredient and the target. <b><i>Results:</i></b> Network pharmacology and ultrahigh-performance liquid chromatography-tandem mass spectrometry analysis revealed that the principal components, catechin, isorhamnetin, and erythrodiol, in DBD&Bor may function as a prospective antimyelosuppression compound. Animal experiments demonstrated that in DBD&Bor, catechin and isorhamnetin could reverse the reduction in hematopoietic stem cell number, the production of stem cell marker (C-kit), and blood cell counts induced by CTX in rats. In addition, CD3, CD4, and CD8α are significantly increased in peripheral blood mononuclear cells, and thymic and splenic pathological damage is significantly attenuated. Also, the improvement effect of catechin was more noticeable. Therefore, the authors chose catechin for further study. Nevertheless, <i>in vivo</i>, overexpression of <i>CDK2</i> negated the beneficial effects of catechin on myelosuppression. <i>In vitro</i> experiments demonstrated that catechin reduced CTX-induced apoptosis and cell cycle arrest in K562 cells by inhibiting <i>CDK2</i>. <b><i>Conclusion:</i></b> The primary component catechin in DBD&Bor inhibits the expression of <i>CDK2</i>, improving CTX-induced myelosuppression in rats and inhibiting apoptosis and cell cycle arrest in K562 cells.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Breakthroughs in Exosome-Based Drug Delivery: A Comprehensive Review for Cancer Therapy.","authors":"Dhwani Shah, Shweta Gandhi, Shreeraj Shah, Kaushika Patel","doi":"10.1089/cbr.2025.0050","DOIUrl":"https://doi.org/10.1089/cbr.2025.0050","url":null,"abstract":"<p><p>Recently, exosomes, or \"natural nanoparticles,\" have been considered as potential drug delivery methods. Due to exosome carriers' natural properties, exosome-mediated drug delivery systems (DDSs) are efficient cancer treatments. Exosomes, small membrane vesicles from many cell types, can transfer phytoconstituents, proteins, nucleic acids, and small molecule medicines across biological boundaries. Recent DDS advances have improved this potential using plant-derived exosomes (PDEs), which are biocompatible and low toxic. PDEs have anticancer effects, especially in the context of conventional treatment resistance, untargeted toxicity, and response variability. This review fills a gap by discussing the latest findings and offering new perspectives on exosome drug delivery in cancer. The study summarizes isolation and loading approaches such as ultracentrifugation and immunological isolation and the characterization parameters for the formulation of exosomes. The exosome-based DDSs are discussed in depth, along with the emphasis on PDEs. The article highlights emerging trends and challenges, including molecular targets and ongoing clinical trials, during the past decade that are critically relevant to the current scenario. Nanotechnology and personalized medicine could improve and lower the cost of exosome-mediated cancer treatment. While the preclinical data have been encouraging, clinical applications of exosome-based therapies are continuing to evolve in its early stages, and some of the problems include scalability, purification, and regulatory compliance.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenomics and Radiopharmaceuticals in Preoperative Chemoradiotherapy: Advancing Personalized Cancer Treatment Protocols.","authors":"Yang Jiao, Shiyu Zheng","doi":"10.1089/cbr.2025.0089","DOIUrl":"https://doi.org/10.1089/cbr.2025.0089","url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Cancer remains a major global health burden, with treatment outcomes often impacted by tumor heterogeneity and individual patient factors. Personalized cancer therapies are increasingly essential to improve prognosis and response. <b><i>Methods:</i></b> This study explores the integration of epigenomics and radiopharmaceuticals into preoperative chemoradiotherapy as a strategy to personalize cancer treatment. Epigenomic profiling identifies reversible heritable changes in gene expression, revealing tumor biology and therapy resistance mechanisms. Radiopharmaceuticals, which combine radioactive isotopes with tumor-specific ligands, enable targeted radiation delivery. <b><i>Results:</i></b> The combined use of epigenetic markers and radiopharmaceuticals allows for tailoring chemoradiotherapy regimens, enhancing tumor selectivity, and minimizing off-target effects. Early clinical data show improved therapeutic efficacy, tumor downstaging, higher survival rates, and reduced recurrence. Epigenetic therapies, including DNA methylation and histone deacetylase inhibitors, further sensitize tumors to radiopharmaceuticals, enhancing treatment synergy. <b><i>Conclusions:</i></b> Integrating epigenomics and radiopharmaceuticals into preoperative chemoradiotherapy represents a significant advancement toward personalized oncology. This approach enhances treatment precision and effectiveness while reducing toxicity. Continued research and clinical validation are critical to transitioning this dual strategy into routine practice.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PGC-1α Promotes NSCLC Progression via FOXM1 Interaction and MUC1 Upregulation.","authors":"Tianyi Zhang, Zhuoshi Li, Shiqing Wang, Shilei Zhao, Chao Gao, Yangfan Qi, Chundong Gu","doi":"10.1089/cbr.2025.0072","DOIUrl":"https://doi.org/10.1089/cbr.2025.0072","url":null,"abstract":"<p><p>Nonsmall cell lung cancer (NSCLC), which constitutes 85%-90% of lung cancer (LC) cases, is among the most frequently diagnosed malignancies. Peroxisome proliferator-activated receptor γ coactivator 1 α (PPARGC1A, also known as PGC-1α) emerges as a major modulator of mitochondrial formation and energy expenditure and serves critical functions in a range of malignancies. Nevertheless, its clinicopathological significance and biological function in the development of NSCLC remain obscure. This investigation revealed that PGC-1α expression exhibited elevated levels in LC. Moreover, enhanced PGC-1α expression augmented the oncogenic potential of NSCLC cells, whereas the downregulation of PGC-1α inhibited the proliferative and migrative capability and suppressed tumor growth <i>in vivo</i>. Mechanistically, PGC-1α interacted with forkhead box protein M1 (FOXM1), a commonly known transcription factor, and enhanced its transcriptional activation of downstream target mucin-1 (MUC1). The ectopic expression of MUC1 could reverse the inhibitory impact of PGC-1α depletion on the proliferation of NSCLC cells. Overall, the data suggested that targeting PGC-1α suppresses NSCLC progression through the FOXM1/MUC1 pathway and potentially offers a novel therapeutic approach for NSCLC treatment.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T Cell Exhaustion-Related Gene Signatures Predict Immunotherapy and Chemotherapy Response in Kidney Renal Clear Cell Carcinoma.","authors":"Chengyu Zou, Jiawen Huang, Zhangjie Jiang, Zehui Rao, Yida Zhang","doi":"10.1089/cbr.2025.0060","DOIUrl":"https://doi.org/10.1089/cbr.2025.0060","url":null,"abstract":"<p><p><b><i>Background:</i></b> Understanding T cell exhaustion (TEX)-related molecular characteristics can provide novel insights into treatment response prediction. This study developed a TEX-based prognostic model to predict survival outcomes and therapy responses in kidney renal clear cell carcinoma (KIRC) patients. <b><i>Methods:</i></b> The authors analyzed 518 KIRC patients from The cancer genome atlas (TCGA), identifying TEX-related genes via gene set variation analysis and weighted correlation network analysis. Survival random forest and Least Absolute Shrinkage and Selection Operator-Cox analyses selected eight key genes to construct a TEX risk model. Functional analyses explored TEX-related pathways and immune infiltration. The IMvigor210 dataset assessed immunotherapy response, whereas the Genomics of Drug Sensitivity in Cancer (GDSC) database predicted chemotherapy sensitivity. Single-cell RNA sequencing and quantitative real-time polymerase chain reaction validated a key TEX gene. <b><i>Results:</i></b> The TEX risk model demonstrated strong prognostic performance, effectively stratifying KIRC patients into high-risk (HR) and low-risk (LR) groups with significant differences in overall survival. Gene set enrichment analysis results revealed that TEX-related pathways were enriched in tumor proliferation, migration, and immune regulation. Immune cell infiltration analysis indicated that the TEX HR group exhibited distinct immune microenvironment characteristics, including increased expression of specific immune checkpoints. The model effectively predicted clinical responses to immunotherapy, with patients in the TEX HR group showing poorer immunotherapy efficacy. In addition, drug sensitivity analysis based on the GDSC database suggested that TEX features could influence chemotherapy response, highlighting potential therapeutic vulnerabilities. Experimental validation confirmed the expression pattern of a key TEX gene in KIRC samples. <b><i>Conclusion:</i></b> Their TEX risk model could effectively predict patient outcomes and responses to immunotherapy and chemotherapy, supporting its potential clinical utility in personalized treatment strategies.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Laparoscopic Myomectomy on Myoglobin, Ischemic Modified Albumin, Total Antioxidant Capacity, Malondialdehyde, and Reactive Oxygen Species in Patients with Uterine Myoma.","authors":"Haiqin Lv, Xin Du, Xiufang Li","doi":"10.1089/cbr.2025.0054","DOIUrl":"https://doi.org/10.1089/cbr.2025.0054","url":null,"abstract":"<p><p><b><i>Objective:</i></b> To find out the effects of laparoscopic myomectomy on myoglobin (MYO), ischemic modified albumin (IMA), total antioxidant capacity (TAC), serum malondialdehyde (MDA), and reactive oxygen species (ROS) in patients with uterine myoma. <b><i>Methods:</i></b> According to different surgical treatment methods, 116 patients with uterine fibroids included from February 2022 to February 2023 were divided into two groups, including a laparotomy group and a laparoscope group. The former (<i>n</i> = 58) underwent open myomectomy, while the latter (<i>n</i> = 58) underwent laparoscopic myomectomy. The indexes of oxidative stress were compared before surgery and on the 1st and 3rd days after surgery. Intraoperative and postoperative recovery indicators and the incidence of postoperative complications were also compared. <b><i>Results:</i></b> Before surgery, there was no significant difference in oxidative stress level between the two groups (<i>p</i> > 0.05). The levels of MYO, IMA, MDA, and ROS decreased in the laparoscope group on the 1st and 3rd days after surgery. The data in the laparotomy group were lower than that in the laparoscope group, so the statistical difference appeared significantly (<i>p</i> < 0.05). The index of TAC in laparoscope group was higher than that in laparotomy group, so the statistical difference was significant (<i>p</i> < 0.05). Data such as the intraoperative time, intraoperative blood loss, the first time to get out of bed, the first time to exhaust, and the first time to eat in laparoscope group were lower than those in laparotomy group, suggesting that the statistical differences were significant (<i>p</i> < 0.05). Three months after surgery, the incidence of incision bleeding, emphysema, nerve damage, intestinal obstruction, and back pain in the laparoscopic group was lower than that in the cesarean section group. The incidence of incision bleeding and nerve damage in this group was 0, while the incidence of incision bleeding in the cesarean section group was as high as 8.62%, significantly higher than that in the laparoscope group (<i>p</i> < 0.05). <b><i>Conclusions:</i></b> It can reduce the oxidative stress of patients and shorten the recovery time of postoperative symptoms, so as to reduce the incidence of complications by means of laparoscopic myomectomy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring <i>SLC25A42</i> as a Radiogenomic Marker from the Perioperative Stage to Chemotherapy in Hepatitis-Related Hepatocellular Carcinoma.","authors":"Lei Dou, Jianhui Jiang, Hongbing Yao, Bo Zhang, Xueyao Wang","doi":"10.1089/cbr.2025.0094","DOIUrl":"https://doi.org/10.1089/cbr.2025.0094","url":null,"abstract":"<p><p><b><i>Background:</i></b> The molecular mechanisms driving hepatocellular carcinoma (HCC) and predict the chemotherapy sensitive remain unclear; therefore, identification of these key biomarkers is essential for early diagnosis and treatment of HCC. <b><i>Method:</i></b> We collected and processed Computed Tomography (CT) and clinical data from 116 patients with autoimmune hepatitis (AIH) and HCC who came to our hospital's Liver Cancer Center. We then identified and extracted important characteristic features of significant patient images and correlated them with mitochondria-related genes using machine learning techniques such as multihead attention networks, lasso regression, principal component analysis (PCA), and support vector machines (SVM). These genes were integrated into radiomics signature models to explore their role in disease progression. We further correlated these results with clinical variables to screen for driver genes and evaluate the predict ability of chemotherapy sensitive of key genes in liver cancer (LC) patients. Finally, qPCR was used to validate the expression of this gene in patient samples. <b><i>Results:</i></b> Our study utilized attention networks to identify disease regions in medical images with 97% accuracy and an AUC of 94%. We extracted 942 imaging features, identifying five key features through lasso regression that accurately differentiate AIH from HCC. Transcriptome analysis revealed 132 upregulated and 101 downregulated genes in AIH, with 45 significant genes identified by XGBOOST. In HCC analysis, PCA and random forest highlighted 11 key features. Among mitochondrial genes, <i>SLC25A42</i> correlated positively with normal tissue imaging features but negatively with cancerous tissues and was identified as a driver gene. Low expression of <i>SLC25A42</i> was associated with chemotherapy sensitive in HCC patients. <b><i>Conclusions:</i></b> In conclusion, machine learning modeling combined with genomic profiling provides a promising approach to identify the driver gene <i>SLC25A42</i> in LC, which may help improve diagnostic accuracy and chemotherapy sensitivity for this disease.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism of Monocarboxylate Transporter 1 and Its Methylation in Nasopharyngeal Carcinoma Pathogenesis.","authors":"Weihong Tong, Zhengyong Zhu, Ruiyang Zhu, Zihe Wang, Jin Zhu","doi":"10.1089/cbr.2025.0106","DOIUrl":"https://doi.org/10.1089/cbr.2025.0106","url":null,"abstract":"<p><p><b><i>Objective:</i></b> This study explores the role of monocarboxylate transporter 1 (<i>MCT1</i>) in nasopharyngeal carcinoma (NPC) metastasis and its regulation via DNA methyltransferase 3B (<i>DNMT3B</i>)-mediated methylation, to identify therapeutic targets for NPC. <b><i>Methods:</i></b> <i>MCT1/DNMT3B</i> expression was analyzed in NPC (<i>n</i> = 30) and normal tissues (<i>n</i> = 30) using quantitative polymerase chain reaction (qPCR) and immunohistochemistry. <i>DNMT3B</i> overexpression plasmids were transfected into NPC cells to assess <i>MCT1</i> expression and promoter methylation via bisulfite sequencing PCR. Luciferase and chromatin immunoprecipitation (ChIP) assays identified <i>DNMT3B-MCT1</i> promoter interactions. Migration/invasion assays and Western blot evaluated functional impacts of <i>MCT1</i> silencing on metastasis-related pathways. Bioinformatic validation utilized GEO datasets. <b><i>Results:</i></b> <i>MCT1</i> mRNA/protein levels were significantly elevated in NPC versus normal tissues (***<i>p</i> < 0.001), whereas <i>DNMT3B</i> was downregulated. <i>DNMT3B</i> overexpression reduced <i>MCT1</i> expression (*<i>p</i> < 0.05) and increased <i>MCT1</i> promoter methylation (**<i>p</i> < 0.01). Luciferase assays revealed that <i>DNMT3B</i> suppressed wild-type <i>MCT1</i> promoter activity, dependent on an 80 bp CpG island (**<i>p</i> < 0.01). ChIP confirmed <i>DNMT3B</i> enrichment at hypermethylated <i>MCT1</i> promoter regions (**<i>p</i> < 0.01). <i>MCT1</i> silencing inhibited NPC cell migration/invasion (*<i>p</i> < 0.05) and downregulated p-AKT, p-mTOR, and p-NFκB (*<i>p</i> < 0.05). High <i>MCT1</i> correlated with Epstein-Barr virus (EBV)-associated EBNA1BP2 (**<i>p</i> < 0.01), but not PD-L1 markers. <i>DNMT3B</i> inversely correlated with <i>MCT1</i> (*<i>p</i> < 0.05) and was upregulated in advanced-stage NPC (Stage III + IV vs. I + II, ***<i>p</i> < 0.001), indicating stage-specific epigenetic dysregulation. <b><i>Conclusion:</i></b> <i>MCT1</i> promotes NPC metastasis via NF-κB and PI3K/AKT/mTOR pathways, regulated by <i>DNMT3B</i>-driven promoter methylation. The <i>MCT1-DNMT3B</i> axis, linked to EBV-associated metabolic reprogramming, represents a prognostic biomarker and therapeutic target for advanced NPC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}